Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
Symbol MARK4 contributors: mct - updated : 21-08-2014
HGNC name MAP/microtubule affinity-regulating kinase 4
HGNC id 13538
Location 19q13.32      Physical location : 45.754.841 - 45.808.541
Synonym name
  • MARK4 serine/threonine protein kinase
  • MAP/microtubule affinity-regulating kinase like 1
  • putative protein product of Nbla00650
  • Synonym symbol(s) MARKL1, KIAA1860, 9b5, Nbla00650, FLJ90097, MARK4L, MARK4S, PAR-1D, MARKL1L
    TYPE functioning gene
    STRUCTURE 54.03 kb     18 Exon(s)
    10 Kb 5' upstream gene genomic sequence study
    MAPPING cloned Y linked N status provisional
    Physical map
    BCL3 19q13.2 B-cell CLL/lymphoma 3 CBLC 19q13.2-q13.3 Cas-Br-M (murine) ecotropic retroviral transforming sequence c LU 19q12-q13 Lutheran blood group (Auberger b antigen included) PVRL2 19q13.2-q13.4 poliovirus receptor-related 2 (herpesvirus entry mediator B) TOMM40 19q13 translocase of outer mitochondrial membrane 40 homolog (yeast) APOE 19q13.2 apolipoprotein E APOC1 19q13.2 apolipoprotein C-I APOC4 19q13.2 apolipoprotein C-IV APOC2 19q13.2 apolipoprotein C-II CLPTM1 19q13.2 cleft lip and palate associated transmembrane protein 1 RELB 19q13.32 v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (avian) SFRS16 19q13.3 splicing factor, arginine/serine-rich 16 (suppressor-of-white-apricot homolog, Drosophila) ZNF342 19q13.32 zinc finger protein 342 GEMIN7 19q13.32 gem (nuclear organelle) associated protein 7 EIF5AP3 19q13.2 eukaryotic translation initiation factor 5A pseudogene 3 LOC284352 19q13.32 hypothetical protein LOC284352 FLJ33600 19q13.32 FLJ33600 protein MGC2650 19q13.32 hypothetical protein MGC2650 LOC388552 19 similar to BC043666 protein XTP7 19q13.32 protein 7 transactivated by hepatitis B virus X antigen (HBxAg) MARK4 19q13.2 MAP/microtubule affinity-regulating kinase 4 CKM 19q13.2 creatine kinase, muscle LOC390943 19 similar to 40S ribosomal protein S16 KLC2L 19q13.3 similar to 40S ribosomal protein S16 ERCC2 19q13.3 excision repair cross-complementing rodent repair deficiency, complementation group 2 (xeroderma pigmentosum D) RAI 19q13.32 RelA-associated inhibitor ASE-1 19q13.3 RelA-associated inhibitor ERCC1 19q13.3 excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence) FOSB 19q13.3 FBJ murine osteosarcoma viral oncogene homolog B RTN2 19q13.3 reticulon 2 VASP 19q13.2-q13.3 vasodilator-stimulated phosphoprotein FLJ40125 19q13.32 hypothetical protein FLJ40125 OPA3 19q13.32 optic atrophy 3 (autosomal recessive, with chorea and spastic paraplegia) GPR4 19q13.3 G protein-coupled receptor 4 EML2 19q13.32 echinoderm microtubule associated protein like 2 GIPR 19q13.3 gastric inhibitory polypeptide receptor SNRPD2 19q13.2 small nuclear ribonucleoprotein D2 polypeptide 16.5kDa FLJ20084 19q13.32 hypothetical protein FLJ20084
    TRANSCRIPTS type messenger
    identificationnb exonstypebpproduct
    ProteinkDaAAspecific expressionYearPubmed
    17 - 5163 - 752 expressed in brain neurogenic regions 2014 25123532
  • MARK4L
  • co-localisation of vimentin and MARK4L suggests that MARK4 has a wide-ranging influence on cytoskeleton
  • exhibits an additional nucleolar localisation in tumour cells
  • 18 - 5243 75.2 688 - 2014 25123532
  • MARK4S
  • MARK4S levels are significantly decreased in glioma and show an inverse correlation with tumour grade
  • in MARK4S silenced cells, centrosomes were duplicated and positioned apically to the nucleus, indicating that the centrosome cycle was altered and the cells arrested in G1 phase
       expressed in (based on citations)
    SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
    Nervousbrain   predominantly
    cell lineage
    cell lines
    at STAGE
    cell cycle     cell cycle
  • catalytic domain
  • ubiquitin associated domain
  • conjugated GlycoP
    interspecies homolog to murine Emk2
    intraspecies homolog to MARK3
  • MARK family of serine-threonine protein kinase
  • microtubule-affinity regulating kinase (MARK) family
  • CATEGORY enzyme
    SUBCELLULAR LOCALIZATION     intracellular
  • localized prominently at the tips of neurite-like processes
  • associated with the basal body and ciliary axoneme
  • expressed throughout the cell cycle and preferentially activated during mitosis
  • basic FUNCTION
  • playing a role in hepatocellular carcinogenesis
  • directly involved in microtubule organization in neuronal cells and may contribute to the pathological phosphorylation of tau in Alzheimer disease
  • MARK1, MARK2, MARK3, MARK4 phosphorylate MAPT in its repeat domain and thereby regulate its affinity for microtubules and affect the aggregation of tau into Alzheimer paired helical filaments
  • is a new negative regulator of MTOR
  • MARK4 kinase activity was required for initiation of axoneme extension 9)
  • is a critical positive regulator of early steps in ciliogenesis
  • MARK1, MARK2, MARK3, MARK4 are implicated in phosphorylation of tau protein, causing formation of neurofibrillary tangles in Alzheimer disease (AD)
  • promotes adipogenesis in adipocytes by activating the MAP2K1 and inhibiting the MAPK14 pathway, and triggers apoptosis by activating the MAP2K1 pathway
  • serine-threonine kinase that phosphorylates MAP proteins, increasing microtubule dynamics
    a component
    small molecule metal binding, nucleotide,
  • PNMA1
  • phosphorylates tau and the related microtubule-associated protein 2 (MAP2) and MAP4
  • phosphorylates Raptor, a key component of MTOR, and this phosphorylation may interfere with Raptor-Rag interaction (increases Raptor Ser-792 phosphorylation, an inhibitory site, to inhibit MTOR)
  • ODF2 is an interaction partner of MARK4 and ODF2 localization to the centriole partially depended on MARK4
  • cell & other
    Other regulated by 14-3-3 scaffolding proteins, as well as the LKB1 tumour suppressor kinase and atypical protein kinase C (PKC)(Göransson 2006)
    corresponding disease(s)
    Variant & Polymorphism
    Candidate gene target for pharmacological intervention in focal cerebral ischaemia
  • MARK4L is a nucleolus-associated tumour marker
  • Therapy target
    diabetemetabolic syndrom 
    anti-Mark4 therapy targetted to inhibit lipid accumulation and apoptosis of adipocytes shows potential as a novel therapeutic strategy for treatment of obesity-associated metabolic complications
    promising target for AD therapy